Citation: Shan-Yang Lin. Salmon calcitonin: conformational changes and stabilizer effects[J]. AIMS Biophysics, 2015, 2(4): 695-723. doi: 10.3934/biophy.2015.4.695
[1] | Fosgerau K, Hoffmann T (2015) Peptide therapeutics: current status and future directions. Drug Discov Today 20: 122-128. doi: 10.1016/j.drudis.2014.10.003 |
[2] | Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 7: 21-39. doi: 10.1038/nrd2399 |
[3] | Craik DJ, Fairlie DP, Liras S, et al. (2013) The future of peptide-based drugs. Chem Biol Drug Des 81: 136-147. doi: 10.1111/cbdd.12055 |
[4] | Bruno BJ, Miller GD, Lim CS (2013) Basics and recent advances in peptide and protein drug delivery. Ther Deliv 4: 1443-1467. doi: 10.4155/tde.13.104 |
[5] | Ratnaparkhi MP, Chaudhari SP, Pandya VA (2011) Peptides and proteins in pharmaceuticals. Int J Curr Pharm Res 3 (2): 1-9. |
[6] | Mullard A (2011) 2010 FDA Approvals. Nat Rev Drug Discov 10: 82-85. doi: 10.1038/nrd3370 |
[7] | Kneller R (2010) The importance of new companies for drug discovery: Origins of a decade of new drugs. Nat Rev Drug Discov 9: 867-882. doi: 10.1038/nrd3251 |
[8] | Uhlig T, Kyprianou TD, Martinelli FG, et al. (2014) The emergence of peptides in the pharmaceutical business: From exploration to exploitation. EuPA Open Proteom 4: 58-69. doi: 10.1016/j.euprot.2014.05.003 |
[9] | Frokjaer S, Otzen DE (2005) Protein drug stability: a formulation challenge. Nat Rev Drug Discov 4: 298-306. doi: 10.1038/nrd1695 |
[10] | van de Weert M, Randolph TW (2012) Physical instability of peptides and pProteins, In: Hovgaard L, Frokjaer S, Van De Weert M, Pharmaceutical Formulation Development of Peptides and Proteins, 2 Eds. , Florida: CRC Press, 107-129. |
[11] | Rathore N, Rajan RS (2008) Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol Prog 24: 504-514. doi: 10.1021/bp070462h |
[12] | Taverna DM, Goldstein RA (2002) Why are proteins marginally stable? Proteins 46: 105-109. doi: 10.1002/prot.10016 |
[13] | Williams PD, Pollock DD, Goldstein RA (2006) Functionality and the evolution of marginal stability in proteins: Inferences from lattice simulations. Evol Bioinform Online 2: 91-101. |
[14] | Chang BS, Yeung B (2010) Physical stability of protein pharmaceuticals, In: Jameel F, Hershenson S, Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals, New Jersey: John Wiley & Sons Inc, 69-104. |
[15] | Lai MC, Topp EM (1999) Solid-state chemical stability of proteins and peptides. J Pharm Sci 88: 489-500. doi: 10.1021/js980374e |
[16] | Chaudhuri R, Cheng Y, Middaugh CR, et al. (2014) High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability. AAPS J 16: 48-64. doi: 10.1208/s12248-013-9539-6 |
[17] | Jacob S, Shirwaikar A, Srinivasan K, et al. (2006) Stability of proteins in aqueous solution and solid state. Indian J Pharm Sci 68: 154-163. |
[18] | Manning MC, Chou DK, Murphy BM, et al. (2010) Stability of protein pharmaceuticals: an update. Pharm Res 27: 544-575. doi: 10.1007/s11095-009-0045-6 |
[19] | Carpenter JF, Manning MC (2002) Rational Design of Stable Protein Formulations: Theory and Practice, New York: Kluwert Academic /Plenum Publishers. |
[20] | Pace CN, Grimsley GR, Scholtz JM, et al. (2014) Protein stability. In: eLS. John Wiley & Sons Ltd, Chichester. Available from: http://onlinelibrary. wiley. com/doi/10. 1002/9780470015902. a0003002. pub3/otherversions |
[21] | Banga AK (2015) Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems, 3 Eds. , Florida: CRC Press. |
[22] | Ohtake S, Wang W (2013) Protein and peptide formulation development. Pharmaceutical Sciences Encyclopedia 11: 1-44. |
[23] | Krishnamurthy R, Manning MC (2002) The stability factor: importance in formulation development. Curr Pharm Biotechnol 3: 361-371. doi: 10.2174/1389201023378229 |
[24] | Cicerone MT, Pikal MJ, Qian KK (2015) Stabilization of proteins in solid form. Adv Drug Deliv Rev doi: 10. 1016/j. addr. 2015. 05. 006. |
[25] | Murphy KP (2001) Protein structure, stability, and folding, Series: Methods in Molecular Biology, Vol. 168, New Jersey: Humana Press. |
[26] | Scheeff ED, Fink JL (2003) Fundamentals of protein structure. Methods Biochem Anal 44: 15-39. |
[27] | Adler MJ, Jamieson AG, Hamilton AD (2011) Hydrogen-bonded synthetic mimics of protein secondary structure as disruptors of protein-protein interactions. Curr Top Microbiol Immunol 348: 1-23. |
[28] | Kwok SC, Mant CT, Hodges RS (2002) Importance of secondary structural specificity determinants in protein folding: insertion of a native beta-sheet sequence into an alpha-helical coiled-coil. Protein Sci 11: 1519-1531. |
[29] | Jorgensen L, Hostrup S, Moeller EH, et al. (2009) Recent trends in stabilizing peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients. Expert Opin Drug Deliv 6: 1219-1230. doi: 10.1517/17425240903199143 |
[30] | Hirsch PF, Baruch H (2003) Is calcitonin an important physiological substance? Endocrine 21: 201-208. doi: 10.1385/ENDO:21:3:201 |
[31] | Huang CL, Sun L, Moonga BS, et al. (2006) Molecular physiology and pharmacology of calcitonin. Cell Mol Biol 52: 33-43. |
[32] | Väänänen K (2005) Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics. Adv Drug Deliv Rev 57: 959-971. doi: 10.1016/j.addr.2004.12.018 |
[33] | Davey RA, Findlay DM (2013) Calcitonin: physiology or fantasy? J Bone Miner Res 28: 973-979. doi: 10.1002/jbmr.1869 |
[34] | Felsenfeld AJ, Levine BS (2015) Calcitonin, the forgotten hormone: does it deserve to be forgotten? Clin Kidney J 8: 180-187. doi: 10.1093/ckj/sfv011 |
[35] | Pondel M (2000) Calcitonin and calcitonin receptors: bone and beyond. Int J Exp Pathol 81: 405-422. |
[36] | Endres DB, Rude RK (1999) Mineral and bone metabolism, In: Burtis CA, Ashwood ER Author, Textbook of Clinical Chemistry, 3 Eds. , Pennsylvania: W B Saunders Company, 1395-1457 |
[37] | Ramasamy I (2006) Recent advances in physiological calcium homeostasis. Clin Chem Lab Med 44: 237-273. |
[38] | Chesnut CH 3rd, Azria M, Silverman S, et al. (2008) Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int 19: 479-491. doi: 10.1007/s00198-007-0490-1 |
[39] | Chakraborty C, Nandi S, Sinha S (2004) Overexpression, purification and characterization of recombinant salmon calcitonin, a therapeutic protein, in Streptomyces avermitilis. Protein Pept Lett 11: 165-173. doi: 10.2174/0929866043478266 |
[40] | O'Connell MB (2006) Prescription drug therapies for prevention and treatment of postmenopausal osteoporosis. J Manag Care Pharm 12(6 Suppl A): S10-9, quiz S26-8. |
[41] | Sexton PM, Findlay DM, Martin TJ (1999) Calcitonin. Curr Med Chem 6: 1067-1093. |
[42] | Windich V, De Luccia F, Herman F, et al. (1997) Degradation pathways of salmon calcitonin in aqueous solution. J Pharm Sci 86: 359-364. doi: 10.1021/js9602305 |
[43] | Torres-Lugo M, Peppas NA (2000) Transmucosal delivery systems for calcitonin: a review. Biomaterials 21: 1191-1196. doi: 10.1016/S0142-9612(00)00011-9 |
[44] | Azria M (2003) Osteoporosis management in day-to-day practice. The role of calcitonin. J Musculoskelet Neuronal Interact 3: 210-213. |
[45] | Karsdal MA, Henriksen K, Arnold M , et al. (2008) Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs 22: 137-144. |
[46] | Azria M, Copp DH, Zanelli JM (1995) 25 years of salmon-calcitonin—from synthesis to therapeutic use. Calcif Tissue Int 57: 405-408. doi: 10.1007/BF00301940 |
[47] | D'Hondt M, Van Dorpe S, Mehuys E, et al. (2010) Quality analysis of salmon calcitonin in a polymeric bioadhesive pharmaceutical formulation: sample preparation optimization by DOE. J Pharm Biomed Anal 53: 939-945. doi: 10.1016/j.jpba.2010.06.028 |
[48] | Hong B, Wu B, Li Y (2003) Production of C-terminal amidated recombinant salmon calcitonin in Streptomyces lividans. Appl Biochem Biotechnol 110: 113-123. doi: 10.1385/ABAB:110:2:113 |
[49] | Andreassen KV, Hjuler ST, Furness SG, et al. (2014) Prolonged calcitonin receptor signaling by salmon, but not human calcitonin, reveals ligand bias. PLoS One 9: e92042. doi: 10.1371/journal.pone.0092042 |
[50] | Stevenson JC, Evans IM (1981) Pharmacology and therapeutic use of calcitonin. Drugs 21: 257-272. doi: 10.2165/00003495-198121040-00002 |
[51] | Renukuntla J, Vadlapudi AD, Patel A, et al. (2013) Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm 447: 75-93. doi: 10.1016/j.ijpharm.2013.02.030 |
[52] | Hoyer H, Perera G, Bernkop-Schnürch A (2010) Noninvasive delivery systems for peptides and proteins in osteoporosis therapy: a retroperspective. Drug Dev Ind Pharm 36: 31-44. doi: 10.3109/03639040903059342 |
[53] | Satoh T, Yoshida G, Orito Y, et al. (1998) Drug delivery system for the treatment of osteoporosis. Nihon Rinsho 56: 742-747. |
[54] | Sinsuebpol C, Chatchawalsaisin J, Kulvanich P (2013) Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery. Drug Des Devel Ther 7: 861-873. |
[55] | Tas C, Mansoor S, Kalluri H, et al. (2012) Delivery of salmon calcitonin using a microneedle patch. Int J Pharm 423: 257-263. doi: 10.1016/j.ijpharm.2011.11.046 |
[56] | Cholewinsky M, Luckel B, Horn H (1996) Degradation pathways, analytical characterization and formulation strategies of a peptide and a protein Calcitonin and human growth hormone in comparison. Pharm Acta Helv 71: 405-419. doi: 10.1016/S0031-6865(96)00049-0 |
[57] | Uda K, Kobayashi Y, Hisada T, et al. (1999) Stable human calcitonin analogues with high potency on bone together with reduced anorectic and renal actions. Biol Pharm Bull 22: 244-252. doi: 10.1248/bpb.22.244 |
[58] | Cudd A, Arvinte T, Das RE, et al. (1995) Enhanced potency of human calcitonin when fibrillation is avoided. J Pharm Sci 84: 717-719. doi: 10.1002/jps.2600840610 |
[59] | Wang W, Roberts CJ (2010) Aggregation of Therapeutic Proteins, 1 Eds. , New Jersey: John Wiley & Sons Inc. |
[60] | den Engelsman J, Garidel P, Smulders R, et al. (2011) Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res 28: 920-933. doi: 10.1007/s11095-010-0297-1 |
[61] | Bryan J (2014) Protein aggregation: formulating a problem. Pharm J 293: 7826. |
[62] | Mahler HC, Friess W, Grauschopf U, et al. (2009) Protein aggregation: pathways, induction factors, and analysis. J Pharm Sci 98: 2909-2934. doi: 10.1002/jps.21566 |
[63] | Brange J, Andersen L, Laursen ED, et al. (1997) Toward understanding insulin fibrillation. J Pharm Sci 86: 517-525. doi: 10.1021/js960297s |
[64] | Shire SJ, Shahrokh Z, Liu J (2004) Challenges in the development of high protein concentration formulations. J Pharm Sci 93: 1390-1402. doi: 10.1002/jps.20079 |
[65] | Thirumangalathu R, Krishnan S, Brems DN, et al. (2006) Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. J Pharm Sci 95: 1480-1497. doi: 10.1002/jps.20619 |
[66] | Wang W, Wang YJ, Wang DQ (2008) Dual effects of Tween 80 on protein stability. Int J Pharm 347: 31-38. doi: 10.1016/j.ijpharm.2007.06.042 |
[67] | Carpenter JF, Pikal MJ, Chang BS, et al. (1997) Rational design of stable lyophilized protein formulations: Some practical advice. Pharm Res 14: 969-975. doi: 10.1023/A:1012180707283 |
[68] | Chi EY, Weickmann J, Carpenter JF, et al. (2005) Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci 94: 256-274. doi: 10.1002/jps.20237 |
[69] | KatakamM, Bell LN, Banga AK (1995) Effect of surfactants on the physical stability of recombinant human growth hormone. J Pharm Sci 84: 713-716. doi: 10.1002/jps.2600840609 |
[70] | Taylor JW, Jin QK, Sbacchi M, et al. (2002) Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues. J Med Chem 45: 1108-1121. doi: 10.1021/jm010474o |
[71] | Karsdal MA, Henriksen K, Arnold M, et al. (2008) Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs 22: 137-144. |
[72] | Kapurniotu A, Taylor JW (1995) Structural and conformational requirements for human calcitonin activity: Design, synthesis, and study of lactam-bridged Analogues. J Med Chem 3: 836-847. |
[73] | Cholewinski M, Lückel B, Horn H. (1996) Degradation pathways, analytical characterization and formulation strategies of a peptide and a protein calcitonine and human growth hormone in comparison. Pharm Acta Helv 71: 405-419. |
[74] | Wang W (1999) Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185: 129-188. |
[75] | Wang W (2000) Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 203: 1-60. |
[76] | Rathore N, Rajan RS (2008) Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol Prog 24: 504-514. doi: 10.1021/bp070462h |
[77] | Krishnamurthy R, Manning MC (2002) The stability factor: importance in formulation development. Curr Pharm Biotechnol 3: 361-371. doi: 10.2174/1389201023378229 |
[78] | Chang SL, Hofmann GA, Zhang L, et al. (2003) Stability of a transdermal salmon calcitonin formulation. Drug Deliv 10: 41-45. doi: 10.1080/713840326 |
[79] | Bauer HH, Aebi U, Häner M, et al. (1995) Architecture and polymorphism of fibrillar supramolecular assemblies produced by in vitro aggregation of human calcitonin. J Struct Biol 115: 1-15. doi: 10.1006/jsbi.1995.1024 |
[80] | Avidan-Shpalter C, Gazit E (2006) The early stages of amyloid formation: biophysical and structural characterization of human calcitonin pre-fibrillar assemblies. Amyloid 13: 216-225. doi: 10.1080/13506120600960643 |
[81] | Diociaiuti M, Gaudiano MC, Malchiodi-Albedi F (2011) The slowly aggregating salmon Calcitonin: a useful tool for the study of the amyloid oligomers structure and activity. Int J Mol Sci 12: 9277-9295. doi: 10.3390/ijms12129277 |
[82] | Seyferth S, Lee G (2003) Structural studies of EDTA-induced fibrillation of salmon calcitonin. Pharm Res 20: 73-80. doi: 10.1023/A:1022250809235 |
[83] | Nakamuta H, Orlowski RC, Epand RM (1990) Evidence for calcitonin receptor heterogenecity: binding studies with non-helical analogs. Endocrinology 127: 163-169. doi: 10.1210/endo-127-1-163 |
[84] | Siligardi G, Samori B, Melandri S, et al. (1994) Correlations between biological activities and conformation properties for human, salmon, eel, porcine calcitonins and Elcatonin elucidated by CD spectroscopy. Eur J Biochem 221: 1117-1125. doi: 10.1111/j.1432-1033.1994.tb18832.x |
[85] | Moriarty DF, Vagts S, Raleigh DP (1998) A role for the C-terminus of calcitonin in aggregation and gel formation: a comparative study of C-terminal Fragments of human and salmon calcitonin. Biochem Biophys Res Commun 245: 344-348. doi: 10.1006/bbrc.1998.8425 |
[86] | van Dijkhuizen-Radersma R, Nicolas HM, van de Weert M, et al. (2002) Stability aspects of salmon calcitonin entrapped in poly(ether-ester) sustained release systems. Int J Pharm 248: 229-237. doi: 10.1016/S0378-5173(02)00458-1 |
[87] | Tang Y, Singh J (2010) Thermosensitive drug delivery system of salmon calcitonin: in vitro release, in vivo absorption, bioactivity and therapeutic efficacies. Pharm Res 27: 272-284. doi: 10.1007/s11095-009-0015-z |
[88] | Windisch V, Deluccia F, Duhau L, et al. (1997) Degradation pathways of salmon calcitonin in aqueous solution. J Pharm Sci 86: 359-364. doi: 10.1021/js9602305 |
[89] | Lucke A, Kiermaier J, Gopferich A (2002) Peptide acylation by poly(α-hydroxy esters). Pharm Res 19: 175-181. doi: 10.1023/A:1014272816454 |
[90] | Montgomerie S, Sundararaj S, Gallin WJ, et al. (2006) Improving the accuracy of protein secondary structure prediction using structural alignment. BMC Bioinformatics 7: 301. doi: 10.1186/1471-2105-7-301 |
[91] | Rost B (2001) Review: protein secondary structure prediction continues to rise. J Struct Biol 134: 204-218. |
[92] | Pirovano W, Heringa J (2010) Protein secondary structure prediction. Methods Mol Biol 609: 327-348. doi: 10.1007/978-1-60327-241-4_19 |
[93] | Kwok SC, Mant CT, Hodges RS (2002) Importance of secondary structural specificity determinants in protein folding: insertion of a native beta-sheet sequence into an alpha-helical coiled-coil. Protein Sci 11: 1519-1531. doi: 10.1110/ps.4170102 |
[94] | Ji YY, Li YQ (2010) The role of secondary structure in protein structure selection. Eur Phys J E Soft Matter 32: 103-107. doi: 10.1140/epje/i2010-10591-5 |
[95] | Haris PI, Chapman D (1995) The conformational analysis of peptides using Fourier transform IR spectroscopy. Biopolymers 37: 251-263. doi: 10.1002/bip.360370404 |
[96] | Manning MC (2005) Use of infrared spectroscopy to monitor protein structure and stability. Expert Rev Proteomics 2: 731-743. doi: 10.1586/14789450.2.5.731 |
[97] | Kong J, Yu S (2007) Fourier transform infrared spectroscopic analysis of protein secondary structures. Acta Biochim Biophys Sinica 39: 549-559 |
[98] | Carpenter JF, Chang BS, Garzon-Rodriguez W, et al. (2002) Rational design of stable lyophilized protein formulations: Theory and practice. Pharm Biotechnol 13: 109-133. doi: 10.1007/978-1-4615-0557-0_5 |
[99] | Chang LL, Pikal MJ (2009) Mechanisms of protein stabilization in the solid state. J Pharm Sci 98: 2886-2908. doi: 10.1002/jps.21825 |
[100] | Wang W (2000) Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 203: 1-60. doi: 10.1016/S0378-5173(00)00423-3 |
[101] | Maa Y-F, Prestrelski SJ (2000) Biopharmaceutical powders: Particle formation and formulation considerations. Curr Pharm Biotechnol 1: 283-302. doi: 10.2174/1389201003378898 |
[102] | Abdul-Fattah AM, Kalonia DS, Pikal MJ (2007) The challenge of drying method selection for protein pharmaceuticals: Product quality implications. J Pharm Sci 96: 1886-1916. doi: 10.1002/jps.20842 |
[103] | Abdul-Fattah AM, Truong-Le V, Yee L, et al. (2007) Drying induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability (I): Stability of a monoclonal antibody. J Pharm Sci 96: 1983-2008. doi: 10.1002/jps.20859 |
[104] | Klibanov AM, Schefiliti JA (2004) On the relationship between conformation and stability in solid pharmaceutical protein formulations. Biotechnol Lett 26: 1103-1106. doi: 10.1023/B:BILE.0000035520.47933.a6 |
[105] | Angkawinitwong U, Sharma G, Khaw PT, et al. (2015) Solid-state protein formulations. Ther Deliv 6: 59-82. doi: 10.4155/tde.14.98 |
[106] | Lee TH, Cheng WT, Lin SY (2010) Thermal stability and conformational structure of salmon calcitonin in the solid and liquid states. Biopolymers 93: 200-207. doi: 10.1002/bip.21323 |
[107] | Stevenson CL, Tan MM (2000) Solution stability of salmon calcitonin at high concentration for delivery in an implantable system. J Pept Res 55: 129-139. doi: 10.1034/j.1399-3011.2000.00160.x |
[108] | Dong A, Huang P, Caughey WS (1990) Protein secondary structures in water from second-derivative amide I infrared spectra. Biochemistry 29: 3303-3308. doi: 10.1021/bi00465a022 |
[109] | Kanari K, Nosaka A (1995) Study of human calcitonin fibrillation by proton nuclear magnetic resonance spectroscopy. Biochemistry 34: 12138-12143. |
[110] | Arvinte T, Drake A (1993) Comparative study of human and salmon calcitonin secondary structure in solutions with low dielectric constants. J Biol Chem 268: 6408-6414. |
[111] | Lee SL, Yu LX, Cai B, et al. (2011) Scientific considerations for generic synthetic salmon calcitonin nasal spray products. AAPS J 13: 14-19. doi: 10.1208/s12248-010-9242-9 |
[112] | Binkley N, Bone H, Gilligan JP, et al. (2014) Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial. Osteoporos Int 25: 2649-2656. doi: 10.1007/s00198-014-2796-0 |
[113] | Murphy LR, Matubayasi N, Payne VA, et al. (1998) Protein hydration and unfolding-insights from experimental partial specific volumes and unfolded protein models. Fold Des 3: 105-118. doi: 10.1016/S1359-0278(98)00016-9 |
[114] | Schiffer CA, Dötsch V (1996) The role of protein-solvent interactions in protein unfolding. Curr Opin Biotechnol 7: 428-432. doi: 10.1016/S0958-1669(96)80119-4 |
[115] | Lee JC (2000) Biopharmaceutical formulation. Curr Opin Biotechnol 11: 81-84. doi: 10.1016/S0958-1669(99)00058-0 |
[116] | Canchi DR, García AE (2013) Cosolvent effects on protein stability. Annu Rev Phys Chem 64: 273-293. doi: 10.1146/annurev-physchem-040412-110156 |
[117] | England JL, Haran G (2011) Role of solvation effects in protein denaturation: from thermodynamics to single molecules and back. Annu Rev Phys Chem 62: 257-277. doi: 10.1146/annurev-physchem-032210-103531 |
[118] | Lee TH, Lin SY (2011) Pluronic F68 enhanced the conformational stability of salmon calcitonin in both aqueous solution and lyophilized solid form. Biopolymers 95: 785-791. |
[119] | Lee TH, Lin SY (2011) Additives affecting thermal stability of salmon calcitonin in aqueous solution and structural similarity in lyophilized solid form. Process Biochem 46: 2163-2169. doi: 10.1016/j.procbio.2011.08.017 |
[120] | Andreotti G, Méndez BL, Amodeo P, et al. (2006) Structural determinants of salmon calcitonin bioactivity: the role of the Leu-based amphipathic alpha-helix. J Biol Chem 281: 24193-24203. doi: 10.1074/jbc.M603528200 |
[121] | Carpenter JF, Prestrelski SJ, Dong A (1998) Application of infrared spectroscopy to development of stable lyophilized protein formulations. Eur J Pharm Biopharm 45: 231-238. doi: 10.1016/S0939-6411(98)00005-8 |
[122] | Haris PI, Chapman D (1994) Analysis of polypeptide and protein structures using Fourier transform infrared spectroscopy. Methods Mol Biol 22: 183-202. |
[123] | Pedone E, Bartolucci S, Rossi M, et al. (2003) Structural and thermal stability analysis of Escherichia coli and Alicyclobacillus acidocaldarius thioredoxin revealed a molten globule-like state in thermal denaturation pathway of the proteins: an infrared spectroscopic study. Biochem J 373: 875-883. doi: 10.1042/bj20021747 |
[124] | Cook TJ, Shenoy SS (2002) Stability of calcitonin salmon in nasal spray at elevated temperatures. Am J Health Syst Pharm 59: 713-715. |
[125] | Lee KC, Lee YJ, Song HM, et al. (1992) Degradation of synthetic salmon calcitonin in aqueous solution. Pharm Res 9: 1521-1523. doi: 10.1023/A:1015839719618 |
[126] | Windisch V, DeLuccia F, Duhau L, et al. (1997) Degradation pathways of salmon calcitonin in aqueous solution. J Pharm Sci 86: 359-364. doi: 10.1021/js9602305 |
[127] | Kamihira M, Naito A, Tuzi S, et al. (2000) Conformational transitions and fibrillation mechanism of human calcitonin as studied by high-resolution solid-state 13C NMR. Protein Sci 9: 867-877. doi: 10.1110/ps.9.5.867 |
[128] | Andreotti G, Motta A (2004) Modulating calcitonin fibrillogenesis: an antiparallel alpha-helical dimer inhibits fibrillation of salmon calcitonin. J Biol Chem 279: 6364-6370. |
[129] | Gaudiano MC, Colone M, Bombelli C, et al. (2005) Early stages of salmon calcitonin aggregation: effect induced by ageing and oxidation processes in water and in the presence of model membranes. Biochim Biophys Acta 1750: 134-145. doi: 10.1016/j.bbapap.2005.04.008 |
[130] | Diociaiuti M, Macchia G, Paradisi S, et al. (2014) Native metastable prefibrillar oligomers are the most neurotoxic species among amyloid aggregates. Biochim Biophys Acta 1842: 1622-1629. doi: 10.1016/j.bbadis.2014.06.006 |
[131] | Gilchrist PJ, Bradshow JP (1993) Amyloid formation by salmon calcitonin. Biochim Biophys Acta 1182: 111-114. doi: 10.1016/0925-4439(93)90160-3 |
[132] | Arvinte T, Cudd A, Drake AF (1993) The structure and mechanism of formation of human calcitonin fibrils. J Biol Chem 268: 6415-6422. |
[133] | Rastogi N, Mitra K, Kumar D, et al. (2012) Metal ions as cofactors for aggregation of therapeutic peptide salmon calcitonin. Inorg Chem 51: 5642-5650. doi: 10.1021/ic202604v |
[134] | Diociaiuti M, Macchia G, Paradisi S, et al. (2014) Native metastable prefibrillar oligomers are the most neurotoxic species among amyloid aggregates. Biochim Biophys Acta 1842: 1622-1629. doi: 10.1016/j.bbadis.2014.06.006 |
[135] | Rawat A, Kumar D (2013) NMR investigations of structural and dynamics features of natively unstructured drug peptide-salmon calcitonin: implication to rational design of potent sCT analogs. J Pept Sci 19: 33-45. doi: 10.1002/psc.2471 |
[136] | Allison SD, Randolph TW, Manning MC, et al. (1998) Effects of drying methods and additives on structure and function of actin: mechanisms of dehydration-induced damage and its inhibition. Arch Biochem Biophys 358: 171-181. doi: 10.1006/abbi.1998.0832 |
[137] | Bhatnagar BS, Bogner RH, Pikal MJ (2007) Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol 12: 505-523. |
[138] | Jain NK, Roy I (2009) Effect of trehalose on protein structure. Protein Sci 18: 24-36. |
[139] | Capelle MA, Gurny R, Arvinte T (2007) High throughput screening of protein formulation stability: practical considerations. Eur J Pharm Biopharm 65: 131-148. doi: 10.1016/j.ejpb.2006.09.009 |
[140] | Kamerzell TJ, Esfandiary R, Joshi SB, et al. (2011) Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev 63: 1118-1159. doi: 10.1016/j.addr.2011.07.006 |
[141] | Ohtake S, Kita Y, Arakawa T (2011) Interactions of formulation excipients with proteins in solution and in the dried state. Adv Drug Deliv Rev 63: 1053-1073. doi: 10.1016/j.addr.2011.06.011 |
[142] | Porfire AS, Tomuţa I, Irache JM, et al. (2009) The influence of the formulation factors on physico-chemical properties of dextran associated Gantrez an nanoparticles. Farmacia 57: 463-472. |
[143] | Torres-Lugo M, Peppas NA (1999) Molecular design and in vitro studies of novel pH-sensitive hydrogels for the oral delivery of calcitonin. Macromolecules 32: 6646-6651. |
[144] | Szelke H, Schübel S, Harenberg J, et al. (2010) Interaction of heparin with cationic molecular probes: probe charge is a major determinant of binding stoichiometry and affinity. Bioorg Med Chem Lett 20: 1445-1447. doi: 10.1016/j.bmcl.2009.12.105 |
[145] | Houska M, Brynda E (1997) Interactions of proteins with polyelectrolytes at solid/liquid interfaces: Sequential adsorption of albumin and heparin. J Colloid Interface Sci 188: 243-250. doi: 10.1006/jcis.1996.4576 |
[146] | Guo B, Anzai J, Osa T (1996) Adsorption behavior of serum albumin on electrode surfaces and the effects of electrode potential. Chem Pharm Bull (Tokyo) 44: 800-803. doi: 10.1248/cpb.44.800 |
[147] | Langer K, Balthasar S, Vogel V, et al. (2003) Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 257: 169-180. doi: 10.1016/S0378-5173(03)00134-0 |
[148] | Prestrelski SJ, Pikal KA, Arakawa T (1995) Optimization of lyophilization conditions for recombinant human interleukin-2 by dried-state conformational analysis using fourier-transform infrared spectroscopy. Pharm Res 12: 1250-1259. doi: 10.1023/A:1016296801447 |
[149] | van Dijkhuizen-Radersma R, Nicolas HM, van de Weert M, et al. (2002) Stability aspects of salmon calcitonin entrapped in poly(ether-ester) sustained release systems. Int J Pharm 248: 229-237. doi: 10.1016/S0378-5173(02)00458-1 |
[150] | Baudys M, Mix D, Kim SW (1996) Stabilization and intestinal absorption of human calcitonin. J Control Rel 39: 145-151. doi: 10.1016/0168-3659(95)00148-4 |
[151] | Sigurjónsdóttir JF, Loftsson T, Másson M (1999) Influence of cyclodextrins on the stability of the peptide salmon calcitonin in aqueous solution. Int J Pharm 186: 205-213. doi: 10.1016/S0378-5173(99)00183-0 |
[152] | Mueller C, Capelle MA, Arvinte T, et al. (2011) Noncovalent pegylation by dansyl-poly(ethylene glycol)s as a new means against aggregation of salmon calcitonin. J Pharm Sci 100: 1648-1662. doi: 10.1002/jps.22401 |
[153] | Mueller C, Capelle MA, Arvinte T, et al. (2011) Tryptophan-mPEGs: novel excipients that stabilize salmon calcitonin against aggregation by non-covalent PEGylation. Eur J Pharm Biopharm 79: 646-657. doi: 10.1016/j.ejpb.2011.06.003 |
[154] | Mueller C, Capelle MA, Seyrek E, et al. (2012) Noncovalent PEGylation: different effects of dansyl-, L-tryptophan-, phenylbutylamino-, benzyl- and cholesteryl-PEGs on the aggregation of salmon calcitonin and lysozyme. J Pharm Sci 101: 1995-2008. doi: 10.1002/jps.23110 |
[155] | Remmele RL, Krishnan S, Callahan WJ (2012) Development of stable lyophilized protein drug products. Curr Pharm Biotechnol 13: 471-496. doi: 10.2174/138920112799361990 |
[156] | Kasper JC, Friess W (2011) The freezing step in lyophilization: physico-chemical fundamentals, freezing methods and consequences on process performance and quality attributes of biopharmaceuticals. Eur J Pharm Biopharm 78: 248-263. doi: 10.1016/j.ejpb.2011.03.010 |
[157] | Costantino HR, Pikal MJ (2004) Lyophilization of Biopharmaceuticals. Virginia: AAPS Press. |
[158] | Susi H, Byler DM (1983) Protein structure by Fourier transform infrared spectroscopy: second derivative spectra. Biochem Biophys Res Commun 115: 391-397. doi: 10.1016/0006-291X(83)91016-1 |
[159] | Prestrelski SJ, Tedeschi N, Arakawa T, et al. (1993) Dehydration-induced conformational transitions in proteins and their inhibition by stabilizers. Biophys J 65: 661-671. doi: 10.1016/S0006-3495(93)81120-2 |
[160] | Lee HE, Lee MJ, Park CR, et al. (2010) Preparation and characterization of salmon calcitonin-sodium triphosphate ionic complex for oral delivery. J Control Rel 143: 251-257. doi: 10.1016/j.jconrel.2009.12.011 |
[161] | Steckel H, Brandes HG (2004) A novel spray-drying technique to produce low density particles for pulmonary delivery. Int J Pharm 278: 187-195. doi: 10.1016/j.ijpharm.2004.03.010 |
[162] | Seville PC, Li HY, Learoyd TP (2007) Spray-dried powders for pulmonary drug delivery. Crit Rev Ther Drug Carrier Syst 24: 307-360. doi: 10.1615/CritRevTherDrugCarrierSyst.v24.i4.10 |
[163] | Sollohub K, Cal K (2010) Spray drying technique: II. Current applications in pharmaceutical technology. J Pharm Sci 99: 587-597. |
[164] | Telko M, Hickey A (2005) Dry powder inhaler formulation. Respir Care 50: 1209-1227. |
[165] | Ameri M, Maa Y (2006) Spray Drying of Biopharmaceuticals: Stability and Process Considerations. Drying Technol: A Int J 24: 763-768. doi: 10.1080/03602550600685275 |
[166] | Chan HK, Clark AR, Feeley JC, et al. (2004) Physical stability of salmon calcitonin spray-dried powders for inhalation. J Pharm Sci 93: 792-804. doi: 10.1002/jps.10594 |
[167] | Yang M, Velaga S, Yamamoto H, et al. (2007) Characterisation of salmon calcitonin in spray-dried powder for inhalation. Effect of chitosan. Int J Pharm 331: 176-181. |
[168] | Sinsuebpol C, Chatchawalsaisin J, Kulvanich P (2013) Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery. Drug Des Devel Ther 7: 861-873. |
[169] | Amaro MI, Tewes F, Gobbo O, et al. (2015) Formulation, stability and pharmacokinetics of sugar-based salmon calcitonin-loaded nanoporous/nanoparticulate microparticles (NPMPs) for inhalation. Int J Pharm 483: 6-18. |
[170] | Lechuga-Ballesteros D, Charan C, Stults CL, et al. (2008) Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci 97: 287-302. doi: 10.1002/jps.21078 |
[171] | Tewes F, Gobbo OL, Amaro MI, et al. (2011) Evaluation of HP βCD-PEG microparticles for salmon calcitonin administration via pulmonary delivery. Mol Pharm 8: 1887-1898. doi: 10.1021/mp200231c |
[172] | Epand RM, Epand RF, Orlowski RC, et al. (1983) Amphipathic helix and its relationship to the interaction of calcitonin with phospholipids. Biochemistry 22: 5074-5084. |
[173] | Epand RM, Epand RF (1986) Conformational flexibility and biological activity of salmon calcitonin. Biochemistry 25: 1964-1968. |
[174] | Green FR 3rd, Lynch B, Kaiser ET (1987) Biological and physical properties of a model calcitonin containing a glutamate residue interrupting the hydrophobic face of the idealized amphiphilic alpha-helical region. Proc Natl Acad Sci U S A 84: 8340-8344. doi: 10.1073/pnas.84.23.8340 |
[175] | Nabuchi Y, Asoh Y, Takayama M (2004) Folding analysis of hormonal polypeptide calcitonins and the oxidized calcitonins using electrospray ionization mass spectrometry combined with H/D exchange. J Am Soc Mass Spectrom 15: 1556-1564. doi: 10.1016/j.jasms.2004.07.007 |
[176] | Siligardi G, Samorí B, Melandri S, et al. (1994) Correlations between biological activities and conformational properties for human, salmon, eel, porcine calcitonins and Elcatonin elucidated by CD spectroscopy. Eur J Biochem 221: 1117-1125. doi: 10.1111/j.1432-1033.1994.tb18832.x |
[177] | Andreotti G, Méndez BL, Amodeo P, et al. (2006) Structural determinants of salmon calcitonin bioactivity: the role of the Leu-based amphipathic alpha-helix. J Biol Chem 281: 24193-24203. doi: 10.1074/jbc.M603528200 |
[178] | Stefani M (2004) Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim Biophys Acta 1739: 5-25. doi: 10.1016/j.bbadis.2004.08.004 |
[179] | Renukuntla J, Vadlapudi AD, Patel A, et al. (2013) Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm 447: 75-93. doi: 10.1016/j.ijpharm.2013.02.030 |
[180] | Choonara BF, Choonara YE, Kumar P, et al. (2014) A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol Adv 32: 1269-1282. doi: 10.1016/j.biotechadv.2014.07.006 |
[181] | Smart AL, Gaisford S, Basit AW (2014) Oral peptide and protein delivery: intestinal obstacles and commercial prospects. Expert Opin Drug Deliv 11: 1323-1335. doi: 10.1517/17425247.2014.917077 |
[182] | Franks F, Hatley RHM, Mathias SF (1991) Materials science and the production of shelf-stable biologicals. Pharm Technol Int 3: 24-34. |
[183] | Slade L, Levine H (1991) Beyond water activity: Recent advances based on an alternative approach to the assessment of food quality and safety. Crit Rev Food Sci Nutri 30: 115-360. doi: 10.1080/10408399109527543 |
[184] | Carpenter JF, Prestrelski SJ, Arakawa T (1993) Separation of freezing- and drying-induced denaturation of lyophilized proteins using stress-specific stabilization. I. Enzyme activity and calorimetric studies. Arch Biochem Biophys 303: 456-464. |
[185] | Carpenter JF, Crowe JH (1989) An infrared spectroscopic study of the interactions of carbohydrates with dried proteins. Biochemistry 28: 3916-3922. doi: 10.1021/bi00435a044 |
[186] | Crowe JH, Crowe LM, Carpenter JF (1993) Preserving dry biomaterials: The water replacement hypothesis, Part 1. BioPharm 6: 28-29, 32-33. |
[187] | Crowe JH, Crowe LM, Carpenter JF (1993) Preserving dry biomaterials: the water replacement hypothesis, Part 2. BioPharm 6: 40-43. |